Skadden ranked first in biotechnology and pharmaceuticals M&A by dollar value for deals globally and in North America according to 2009 year-end rankings from BioPharm Insight. The firm led all others with 13 deals valued at $156.8 billion. BioPharm Insight is a subsidiary of the Financial Times Group.
Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates